-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

An MCL Quiz Game: Experts Review New and Emerging Therapies to Optimize Clinical Outcomes

Sponsor: an educational grant from AstraZeneca. Provided by Clinical Care Options, LLC.
Program: Friday Satellite Symposia
Hematology Disease Topics & Pathways:
Diseases, Therapies
Friday, December 8, 2023: 11:00 AM-2:00 PM
Pacific Ballroom Salons 21-22 (Marriott Marquis San Diego Marina)
John P. Leonard, Weill Cornell Medicine
Leonard: National Cancer Institute, Leukemia and Lymphoma Society, Genentech, Epizyme, Janssen: Research Funding; AbbVie, AstraZeneca, Astellas, Bayer, BeiGene, BMS, Calithera, Constellation, Eisai, Epizyme, GenMab, Grail, Incyte, Janssen, Karyopharm, Lilly, Merck, Mustang Bio, Pfizer, Roche/Genentech, Seagen, Second Genome, Sutro: Consultancy.
Matthew A. Lunning, DO, FACP, Heme/Onc, University of Nebraska and Ann LaCasce, MD, Dana-Farber Cancer Institute
Lunning: GenMab: Consultancy, Honoraria; InstilBio: Consultancy, Honoraria; Ipsen: Consultancy, Honoraria; Pharmacyclics: Consultancy, Honoraria; Nurix: Consultancy, Honoraria; Novartis: Consultancy, Honoraria; Morphosys: Consultancy, Honoraria; Miltenyi: Consultancy, Honoraria; Loxo: Consultancy, Honoraria; Kite: Consultancy, Honoraria; Janssen: Consultancy, Honoraria; Regeneron: Consultancy, Honoraria; Sanofi: Consultancy, Honoraria; Genentech: Consultancy, Honoraria; Fate Therapeutics: Consultancy, Honoraria; EUSA: Consultancy, Honoraria; Daiichi Sankyo: Consultancy, Honoraria; CRISPR: Consultancy, Honoraria; Caribou: Consultancy, Honoraria; BMS: Consultancy, Honoraria, Research Funding; Astellas: Consultancy, Honoraria; Astra Zeneca: Consultancy, Honoraria; ADC Therapeutics: Consultancy, Honoraria; Acrotech: Consultancy, Honoraria; AbbVie: Consultancy, Honoraria; SeaGen: Consultancy, Honoraria; Takeda: Consultancy, Honoraria; TG Therapeutics: Consultancy, Honoraria; Curis: Research Funding. LaCasce: Seagen, Kite Pharma: Membership on an entity's Board of Directors or advisory committees; Research to Practice: Consultancy.
The treatment of mantle cell lymphoma (MCL) is evolving. Join us for this innovative live satellite symposium that will feature a review and discussion of key clinical trial data with renowned clinical experts providing their perspectives focused specifically on BTK inhibitor-based therapy. In addition, enjoy a little friendly competition during the symposium as you will be challenged with a series of patient cases and polling questions presented as part of a Team Trivia style quiz game. Additionally, attendees will have ample ability to directly interact with the expert panel and contribute to the content of the program via submission of questions. Critical insights on the similarities and differences among multiple different BTK inhibitors will help prepare attendees to safely and effectively use these agents in their practice. Discussion and case topics will include: 1) Recent updates to the treatment landscape in MCL; 2) Mechanisms, pharmacokinetics, pharmacodynamics, and efficacy of currently available BTK inhibitors; 3) The evolving role of BTK inhibitors in treatment-naïve MCL; 4) The management of relapsed/refractory disease considering resistance or intolerance to prior therapy; 5) Practical discussions with multiple expert perspectives on the implementation of new data and current clinical challenges.